Extrahepatic Metastasis in Hepatocellular Carcinoma
Summary
Extrahepatic metastasis in hepatocellular carcinoma (HCC) denotes the spread of primary liver malignancies beyond the hepatic parenchyma to distant organs. The most common sites include lung, bone and lymph nodes. The emergence of extrahepatic lesions signifies a more aggressive tumour biology, compounding the already complex management of HCC. Patients with metastases outside the liver often present with advanced symptoms and diminished liver function, limiting local treatments. Historically, systemic therapies have offered only modest benefits, and the prognosis remains poor, with median survival measured in months. Recent advances have begun to unravel underlying mechanisms of tumour dissemination, highlight predictive biomarkers and refine combined modality approaches. A clearer understanding of the metastatic cascade, from intravasation to colonisation of secondary sites, is informing the design of novel agents and locoregional strategies aimed at extending survival and preserving quality of life.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Extrahepatic Metastasis in Hepatocellular Carcinoma publication trend
The graph below shows the total number of articles in extrahepatic metastasis in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).
Technical terms
Extrahepatic metastasis: Spread of hepatocellular carcinoma cells to organs outside the liver.
Oligometastasis: State of limited metastatic disease, typically defined as up to five lesions that may be amenable to local therapy.
Overall survival (OS): Time from initiation of treatment until death from any cause, used as a primary efficacy endpoint.
Progression-free survival (PFS): Interval from treatment start to documented disease progression or death, reflecting control of tumour growth.
Palliative treatment: Therapy aimed at symptom relief and life-extension rather than cure, often employed in advanced-stage cancer.
References
- Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. Signal Transduction and Targeted Therapy (2023).
- Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clinical and Translational Medicine (2023).
- Local Treatment of Hepatocellular Carcinoma with Oligometastases: A Systematic Review and Meta-Analysis. Cancers (2023).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.